GILD - ギリアド・サイエンシズ (Gilead Sciences Inc.) ギリアド・サイエンシズ

 GILDのチャート


 GILDの企業情報

symbol GILD
会社名 Gilead Sciences Inc (ギリアド・サイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ギリアド・サイエンシズ(Gilead Sciences Inc.)は医薬品の発見・開発・商業化を行う研究型バイオ医薬品会社である。同社の製品ポートフォリオと治験薬のパイプラインはヒト免疫不全ウイルス、後天性免疫不全症候群(HIV/AIDS)、肝疾患、癌、炎症、呼吸器疾患、心血管疾患を含む。HIV/AIDS患者用製品は「Descovy」、「Odefsey」、「Genvoya」、「Stribild」、「Complera」、「Eviplera」、「Truvada」、「Emtriva」、「Tybost」、「Vitekta」を含む。肝臓疾患患者用製品は「Vemlidy」、「Epclusa」、「Harvoni」、「Sovaldi」、「Viread」、「Hepsera」を含む。同社は血液学・腫瘍疾患の患者にZydeligを提供する。心臓血管疾患の患者用製品は「Letairis」、「Ranexa」、「Lexiscan」を含む。炎症・呼吸器疾患治療用の製品は「Cayston」と「Tamiflu」を含む。   ギリアド・サイエンシズは米国の医薬品会社。主要製品は抗HIV薬の「ツルバダ」、「アトリプラ」、B型肝炎治療薬「ヘプセラ」、「ビリア―ド」、侵襲性真菌感染症治療薬「アンビゾ―ム」、肺動脈高血圧症治療薬「レタイリス」、サイトメガロウイルス性網膜炎治療薬「ビスタイド」、慢性狭心症治療薬「ラネクサ」など。本社はカリフォルニア州。   Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
本社所在地 333 Lakeside Drive Foster City CA 94404 USA
代表者氏名 John C. Martin ジョンC.マーティン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 650-574-3000
設立年月日 31929
市場名 NASDAQ National Market System
ipoyear 1992年
従業員数 10000人
url www.gilead.com
nasdaq_url https://www.nasdaq.com/symbol/gild
adr_tso
EBITDA EBITDA(百万ドル) 11943
終値(lastsale) 76.4
時価総額(marketcap) 99040421305.2
時価総額 時価総額(百万ドル) 94982.88
売上高 売上高(百万ドル) 23197
企業価値(EV) 企業価値(EV)(百万ドル) 98125.88
当期純利益 当期純利益(百万ドル) 7690
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Gilead Sciences Inc. revenues decreased 21% to $10.74B. Net income before extraordinary items decreased 42% to $3.35B. Revenues reflect Antiviral products segment decrease of 26% to $9.14B. Net income also reflects Research and development expenses increase of 19% to $2.13B (expense) Selling general and administrative expe increase of 13% to $1.98B (expense).

 GILDのテクニカル分析


 GILDのニュース

   Why Gilead Stock Is a Good Buy for the Long Term  2020/02/14 16:06:01 Money Morning
Gilead stock is set to break out its doldrums with the company taking steps to reinvigorate its drug pipeline. Here's why now is the time to buy GILD stock…
   Medicamento previne tipo de coronavírus em macacos e aumenta esperanças para testes na China  2020/02/13 23:52:00 Extra
Por Julie SteenhuysenCHICAGO (Reuters) - Um medicamento antiviral experimental da Gilead Sciences preveniu a doença e reduziu a gravidade dos sintomas em macacos infectados com a Síndrome Respiratória do Oriente Médio… Leia mais
   3 Biotech Stocks That Made Early Shareholders Millionaires | The Motley Fool  2020/02/13 14:49:00 The Motley Fool
Amgen, Biogen, and Gilead Sciences have each transformed their early investors.
   Gilead scrambles to develop first drug for Coronavirus  2020/02/12 16:35:00 MarketWatch
If Gilead’s experimental drug succeeds, it could become the first treatment proven to work against the virus that has killed more than 1,000 people in three…
   Chinese company claims it can make Gilead’s coronavirus drug  2020/02/12 07:41:49 Free Malaysia Today
News adds to concerns the American drug giant is losing patent control.
   The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight  2020/02/09 20:22:37 Benzinga
Biotech stocks recovered last week along with the broader markets, which bounced back from a China coronavirus-induced sell-off. Big pharma earnings took the spotlight, with Merck & Co., Inc. (NYSE: MRK ), Bristol-Myers Squibb Co (NYSE: BMY ), Gilead Sciences, Inc. (NASDAQ: GILD ) and AbbVie Inc (NYSE: ABBV ) among the notable ones reporting in the week. Merck surprised the markets by announcing plans to spin-off its slow-growing Women's Health, Legacy Brands and Biosimilars business. Here're the key biotech catalysts for the unfolding week. Conferences Bio CEO & Investor Conference: Feb. 10-11 in New York 16th Annual WORLDSymposium: Feb. 10-13 in Orlando, Florida Guggenheim Healthcare Talks/Oncology Day: Feb. 13 in New York ASCO 2020 Genitourinary Cancers Symposium: Feb. 13-15 in San Francisco, California Adcom Meeting FDA's Tobacco Products Scientific Advisory Committee is scheduled to meet Friday to discuss the modified risk tobacco product applications submitted by 22nd Century Group Inc (NYSE: XXII ) for VLN King and VLN Menthol King combusted, filtered cigarettes.
   Prudential Financial, Gilead, and 3M Raised Dividends Last Week  2020/02/08 13:00:00 MarketWatch
Biotech company Gilead Sciences is increasing its quarterly dividend to 68 cents a share, an 8% boost, and Prudential declared a 10% dividend increase.
   There's a good chance the Wuhan coronavirus will never disappear, experts say. There are only 3 possible endings to this story.  2020/02/07 20:33:00 Business Insider
A coronavirus outbreak that originated in Wuhan, China, has killed at least 630 people and infected more than 31,500 across 26 countries. According to one expert, the coronavirus is now "a mild pandemic ." Here are three ways that experts think the coronavirus pandemic could play out. Most likely, the outbreak will never truly end. Visit Business Insider's homepage for more stories . A coronavirus outbreak that started in Wuhan, China, in December has killed at least 630 people and infected more than 31,500 across 26 countries. According to public-health experts, there are only three possible endings to this coronavirus story: The outbreak could be controlled via public-health interventions and disappear (as SARS did), a vaccine could be developed, or the coronavirus will become a permanent part of the repertoire of human viruses, perhaps like seasonal flu. That third option is the most likely, two experts told Business Insider — the new virus may never truly disappear. "Right now, the actions being taken in China — the Draconian efforts — are what happens when you're trying to catch a galloping horse that's already left the barn," Stephen Morse, an epidemiologist at Columbia University, said.
   Gilead an acquisition target? Deep pockets required  2020/02/07 17:11:04 Seeking Alpha
Jefferies' Michael Yee says investors believe that Gilead Sciences (GILD +0.6%) is an acquisition target considering its near-term share performance (at th
   Global NASH Market & Drug Pipeline Insights, 2020-2025, Featuring Intercept, Genfit, Allergan, Madrigal, Immuron, Galectin, and Gilead  2020/02/07 14:15:00 PR Newswire
DUBLIN, Feb. 7, 2020 /PRNewswire/ -- The "NASH Drug Pipeline and Market Overview" report has been added to ResearchAndMarkets.com's offering. No medications have been approved specifically for NASH but there are numerous products in development. NASH Drug Pipeline and Market Overview…
  ブリストル・マイヤーズがギリアドに対する米国特許訴訟で7億5200万米ドルを勝ち取る Bristol-Myers wins US$752 million in US patent case against Gilead  2019/12/13 22:35:24 Channel NewsAsia
「金曜日のブリストル・マイヤーズスクイブ社は、癌治療技術に関する米国特許紛争で、ギリアドサイエンス社に対する7億5200万米ドルのju審評決を獲得したと述べました。
Bristol-Myers Squibb Co on Friday said it won a US$752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer.
   Bristol-Myers prevails over Gilead in Yescarta royalty row: Bloomberg Law  2019/12/13 20:12:56 Reuters
Bristol-Myers Squibb Co won a patent infringement trial against Gilead Sciences Inc's unit Kite Pharma over cancer immunotherapy Yescarta, Bloomberg Law reported on Friday.
   Top Analyst Upgrades and Downgrades: Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap, Wayfair and More  2019/12/13 14:00:16 24/7 Wall street
   Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy  2019/12/12 14:59:00 Zacks Investment Research
Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.
   How to democratize access and prevent the next supermodel medicine  2019/12/11 12:52:41 IHS Markit
"Supermodel" is not a term I was expecting to hear at this year's ISPOR Europe conference in Copenhagen, which had the Digital Transformation of Healthcare as its overarching theme. But then again, the term made sense in the context of a session on personalised precision medicine. Jan Geissler, founder of patient cancer advocacy group Patvocates, questioned whether there is a danger with genomic testing and advanced therapies (such as CAR-T therapies) of "creating the next supermodel medicine: lovely to look at, very costly, accessible only to a few, and of real value to many?" Speakers during this Special Interest Group session reiterated precision medicine's potential to improve outcomes without increasing healthcare costs. Case in point, precision medicine has played an important role in declining mortality rates (specifically five-year cancer survival rates) in a range of cancer indications in the US. However, to unlock the full potential of precision medicine, access to diagnostics and treatment is key.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ギリアド・サイエンシズ GILD Gilead Sciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)